Actively Recruiting
Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer
Led by Zhejiang Cancer Hospital · Updated on 2024-09-05
1100
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project aims to collect peripheral blood samples from newly diagnosed gastric cancer patients and healthy individuals. Various techniques such as cfDNA sequencing, proteomics, and fragmentomics will be employed to analyze differences in the expression of ctDNA mutations, fragmentomics, and protein biomarkers between gastric cancer patients and healthy individuals. A new comprehensive diagnostic model will be established and its diagnostic value (sensitivity, specificity, accuracy, etc.) for gastric cancer will be validated. Specifically, the study will involve the following subjects and quantities: 700 participants from Zhejiang Cancer Hospital (350 gastric cancer patients and 350 healthy individuals), 200 participants from Sichuan Cancer Hospital (100 gastric cancer patients and 100 healthy individuals), and 200 participants from the Sixth Affiliated Hospital of Sun Yat-sen University (100 gastric cancer patients and 100 healthy individuals). Peripheral blood samples (a total of 15mL from each participant, collected in 3 tubes) will be collected from all subjects. The collected blood samples will undergo multi-omics sequencing including cfDNA methylation sequencing, proteomics, and genomics to establish a multi-omics-based early diagnostic model.
CONDITIONS
Official Title
Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 100 years
- ECOG performance status of 0 or 1
- Pathologically confirmed Stage I-III gastric cancer patients
- No prior anti-tumor treatment before blood collection, including chemotherapy, radiotherapy, targeted therapy, surgery, or anesthesia
- Ability to understand the study and provide written informed consent along with family support
You will not qualify if you...
- Other hereditary diseases or tumors
- Severe inflammatory reactions from acute illnesses within 14 days before blood draw or steroid use
- Previous organ, stem cell, or bone marrow transplantation, or blood transfusion within one month before enrollment
- Pregnant women
- Participation in other clinical trials involving medication within 60 days, including anesthesia
- Severe cardiovascular diseases, uncontrolled infections, or other uncontrollable comorbidities
- Inability of participant or family to understand study conditions and objectives
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
X
Xiangdong Cheng, Professor
CONTACT
L
Li Yuan, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here